Evaluating many treatments and biomarkers in oncology: a new design - Wikidata - wikimedia - TriplyDB

Evaluating many treatments and biomarkers in oncology: a new design

Evaluating many treatments and biomarkers in oncology: a new design

http://www.wikidata.org/entity/Q35379179

about

Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer Adaptive designs undertaken in clinical research: a review of registered clinical trials Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review Surgery in the era of the 'omics revolution Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.Pancreatic cancer genomics: where can the science take us?Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer.Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial Lung cancer in the era of precision medicine Next-Generation Sequencing to Guide Clinical Trials.Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.The Master Protocol Concept.Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial.Clinical trial designs incorporating predictive biomarkers.Immunotherapy in glioblastoma: emerging options in precision medicine Expansion platform type II: testing a treatment strategy.Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Prioritizing targets for precision cancer medicine.Case histories in unresectable liver-dominant metastatic colorectal cancer.Optimizing drug development in oncology by clinical trial simulation: Why and how?Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints.Cancer predisposition syndromes: lessons for truly precision medicine.Toward Personalized Targeted Therapeutics: An Overview.Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.Comparing a stratified treatment strategy with the standard treatment in randomized clinical trials.A Bayesian adaptive design for biomarker trials with linked treatments.From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting.Spotlight on landmark oncology trials: the latest evidence and novel trial designs.Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine.Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.Addressing small sample size bias in multiple-biomarker trials: Inclusion of biomarker-negative patients and Firth correction.Definitions and statistical properties of master protocols for personalized medicine in oncology.Rare cancers: the greatest inequality in cancer research and oncology treatment.Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.Precision oncology: A new era of cancer clinical trials.Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.Adaptive designs in clinical trials: why use them, and how to run and report them.Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements.

P2860

Q26747329-31D51643-BC29-4ECB-A74A-D371794C67A2 Q26753245-119EC297-2A7B-4E44-901B-4B386BD5BFCB Q26766584-218B8390-8104-4CB4-95BC-C6A9EA6B9DD5 Q26852061-60C0B88A-C6B8-4C91-B4CB-9BF21E076117 Q26992272-6592702C-6472-47EC-8CB6-804CA0ED5B69 Q33555283-F45F2044-2488-44BD-93C5-5356A6CE0DC3 Q33576199-41EF597A-C485-4931-96FA-3523BA5FC27A Q34447458-3BFC4FB5-720F-494B-873B-47FF37B692E5 Q34528276-0989DD22-7E51-46D5-A9EB-2CA26B4B64A3 Q35168763-EFF62BBF-BDB7-4419-9F47-E0238F064A6A Q35861107-45E3B9F6-BE13-40DD-95FA-BB16DD6126B3 Q36174832-47F9109D-7E45-4618-9C0C-FA27730515C7 Q36303134-EE3FBC0C-C8DA-4F87-8324-542B5C5426E2 Q36377768-4EC3B5FE-9343-446F-9DC7-BF7ECC84063B Q36475718-0FA23130-48F8-4738-BB9C-EDCCE0F752BD Q36534713-3F76F80A-A142-4A86-80C7-0CC44535E830 Q37050960-88094A62-2E8B-4A36-836B-3F25289F783F Q37181647-AD195B1E-5525-4C0C-AA44-42D8E40AE63A Q37731264-4E06B5D7-D808-4CFB-BC37-F07523658668 Q38262620-EC0051F7-59C0-4B23-ADC5-F79DD95F3486 Q38283664-3C084C41-62A1-4913-AC02-91366E87CCEF Q38675644-B9A66DAC-8329-4FD2-9C0F-426A5852E488 Q38927246-5D49F61C-95EC-4E1E-9B2A-0371454C2CC3 Q39012229-83972CF8-81E2-48C2-9569-7ED45EE917D3 Q39044141-73D7996E-B28E-4D9D-8B88-59AA23DB02A4 Q39126105-45D484D8-A1DA-4623-B0F0-DBD82D860C08 Q40566508-07CA9D87-B76B-482C-9699-A42681926838 Q41835806-2B7D8334-8070-4DF0-B25A-5FF404386E6A Q42337513-8FD55D12-1785-4595-9005-20AE3A18D737 Q42343618-98B74979-981A-443D-8F1E-C55B2B9E2025 Q42415361-8EE85666-64D7-4E13-A0E3-ED92C7984A47 Q47190268-792D96C6-1DBD-4980-B435-FC822ADB544C Q47197037-D1AD3888-8EB2-4A42-B0CF-D4CD6FA2B911 Q47322951-FB853B70-4194-4790-853E-73EFB34F9578 Q47684518-59C82D51-D034-4D95-870B-BD65B44DCD4E Q50099775-8EE490B4-EB8B-41EF-AF13-0DCAB158261C Q50355746-88F81324-9982-4D11-B4FA-8A04076D49AA Q50498479-AAE4EE8D-56A9-4A37-96A0-982BF58F2F98 Q52681001-689291C2-72C8-4FF6-BB61-7CDC52EE66CE Q52690719-7713ABBA-CA4B-4956-AB73-0AA07B333070

P2860

Evaluating many treatments and biomarkers in oncology: a new design

http://www.wikidata.org/entity/Q35379179

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Evaluating many treatments and biomarkers in oncology: a new design

@ast

Evaluating many treatments and biomarkers in oncology: a new design

@en

type

label

Evaluating many treatments and biomarkers in oncology: a new design

@ast

Evaluating many treatments and biomarkers in oncology: a new design

@en

prefLabel

Evaluating many treatments and biomarkers in oncology: a new design

@ast

Evaluating many treatments and biomarkers in oncology: a new design

@en

P1433

Q35379179-56DA04A2-1E9D-48CA-ADFE-7D3CF5D932AA

P1476

Q35379179-2716B996-E85A-4771-8D02-040AFAD2E33E

P2093

Q35379179-28AEED3E-A234-47E7-BB62-230E9642208D

Q35379179-670FC8BB-B050-4032-9107-78D9CBDE21EB

Q35379179-6780ABDD-44CC-4F26-B4D2-8E80FFA60114

Q35379179-898E726A-2E9E-4D6E-B97E-DB8B0C9A90FA

Q35379179-A5A38CED-BE29-4ADB-8727-934A71A87B0C

Q35379179-B8B5D49E-3743-4F95-9313-D14B1C0E992D

Q35379179-CD73EDF9-EA02-4514-A3DA-1ED163F475A5

P2860

Q35379179-021118C0-EB43-455C-A411-CB67B80FB535

Q35379179-0279DE36-FDF3-4213-9003-6016148B44D7

Q35379179-03490B32-3258-482E-A160-49EDE8E22963

Q35379179-08DC1E00-7F63-4713-BBEC-91591EF84B6D

Q35379179-09AE860F-D61D-4D0D-A26A-9B04CA124F3D

Q35379179-0ADC8055-A773-4080-B8C1-EBB64EA9963B

Q35379179-0FBAD8A5-DF41-417B-AAA1-AF4AB34C9A66

Q35379179-10EF822E-23AA-480F-B513-31BA7AE87ECC

Q35379179-175AEE06-1B71-4B8B-98DB-BF15A48DC745

Q35379179-1DA00193-084F-422B-97BB-3D5614D20534

P304

Q35379179-36185AF9-36A2-4DC9-B02E-287091CFE06B

P31

Q35379179-F12335A1-E0C4-4E38-BDC8-DCE3A6EA31F1

P356

Q35379179-C7181DF0-097C-4341-A1E1-B49CEB169078

P407

Q35379179-25CCB0DE-140E-4FDC-A10A-A8629B5F7572

P433

Q35379179-762879B7-CF27-4B53-9B65-BC116BDDEFD3

P478

Q35379179-8A2850DF-269E-4065-8E37-B4986C0D6076

P577

Q35379179-A20AA9E7-0135-4B99-9913-D3ABA4515997

P698

Q35379179-D44D7C84-7526-49C5-9219-2A0B7E5146A2

P921

Q35379179-970D4DE0-8E4F-4728-B446-F51A9D1B4F35

P932

Q35379179-7DBE6C18-8E65-451A-9153-B237AC749163

P356

JCO.2013.50.7905

P1433

Journal of Clinical Oncology

P1476

Evaluating many treatments and biomarkers in oncology: a new design

@en

P2093

Angela Crook

http://www.w3.org/2001/XMLSchema#string

David Fisher

http://www.w3.org/2001/XMLSchema#string

Louise Brown

http://www.w3.org/2001/XMLSchema#string

Mahesh Parmar

http://www.w3.org/2001/XMLSchema#string

Richard Kaplan

http://www.w3.org/2001/XMLSchema#string

Richard Wilson

http://www.w3.org/2001/XMLSchema#string

Timothy Maughan

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Clinical trial designs for predictive marker validation in cancer treatment trials

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.

Effective incorporation of biomarkers into phase II trials

P304

4562-4568

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.50.7905

http://www.w3.org/2001/XMLSchema#string

P407

P433

36

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24248692

http://www.w3.org/2001/XMLSchema#string

P921

P932

4394353

http://www.w3.org/2001/XMLSchema#string